阿格列汀与吡格列酮联合治疗2型糖尿病的疗效及对胰岛β细胞功能改善的影响

Efficacy of alogliptin combined with pioglitazone in treatment of patients with type 2 diabetes and its influence on improvement of islet β cell function

目的探讨阿格列汀与吡格列酮联合治疗2型糖尿病的疗效及对胰岛β细胞功能改善的影响。方法选取T2DM患者79例,采用随机数字表法分为安慰剂(PBO)组(n=26)、阿格列汀组(ALO)组(n=26)和阿格列汀/吡格列酮(ALO/PIO)组(n=27)。16周后,对比3组指标变化及临床疗效。结果 3组患者服药16周后,FPG、2 h PG、HbAlc、HOMAIR、HOMA-β指数比较,差异有统计学意义(P<0.05)。结论联合应用ALO/PIO治疗可以改善血糖控制,减轻胰岛素抵抗,改善胰岛β细胞功能。

Objective To explore the efficacy of alogliptin combined with pioglitazone on treatment of patients with type 2 diabetes and its influence on improvement of islet β cell function. Methods A total of 79 T2DM patients were randomly divided into PBO group （n = 26）, ALO group （ n = 26） and ALO/PIO group （ n = 27 ）. After 16 weeks of treatment, the clinical efficacy and changes of related indexes were compared. Results After 16 weeks of treatment, there were significant differences in FPG, 2 h PG, HbAlc, HOMA-IR and HOMA-β among three groups （P 〈 0.05）. Conclusion Combined ALO/PIO therapy can improve glycemic control, reduce insulin resistance and improve islet β cell function.